Investment Thesis
Rocket Pharmaceuticals is a pre-revenue biotech company with catastrophic burn rate ($190M annually) against minimal cash reserves ($77.6M), implying critical liquidity crisis within ~5 months without external funding. While the balance sheet shows low debt and improving loss trends, the fundamental lack of revenue combined with unsustainable operational burn presents existential risk.
Strengths
- Low leverage with zero long-term debt and strong equity base of $277.2M
- Improving loss trajectory with net loss down 13.8% year-over-year
- Exceptional liquidity ratios (6.38x current/quick) provide near-term operational flexibility
Risks
- Critical cash runway of approximately 5 months at current burn rate ($190M annual operating cash burn vs $77.6M cash)
- Zero revenue indicates failed or stalled pipeline with no near-term commercial viability
- Unsustainable cash burn with no visible path to profitability, creating imminent dilution or bankruptcy risk
Key Metrics to Watch
- Monthly cash burn rate and cash position relative to runway
- Pipeline progress, clinical trial results, and FDA approval milestones
- Funding announcements, partnerships, or strategic transactions
Financial Metrics
Revenue
0.0
Net Income
-223.1M
EPS (Diluted)
$-2.01
Free Cash Flow
-190.5M
Total Assets
330.4M
Cash
77.6M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-80.5%
ROA
-67.5%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
6.38x
Quick Ratio
6.38x
Debt/Equity
0.00x
Debt/Assets
16.1%
Interest Coverage
-122.55x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-15T01:54:19.743835 |
Data as of: 2025-12-31 |
Powered by Claude AI